Similar to chemotherapy-treated colon cancer (37), increased FAK tyrosine phosphorylation is detected in avutometinib-treated KRAS-mutated NSCLC cells (25) wherein FAK activation in this context may represent an adaptive or intrinsic cell resistance mechanism. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.